Introduction
============

HIV infection/AIDS has continued to be one of the top priorities of the health sector program of the Ethiopian government.[@b1-hiv-9-153] Of the estimated 593,400 adults living with HIV, 298,512 were on treatment by the end of 2013. More than 45,200 people died due to AIDS in the same year.[@b2-hiv-9-153]

Highly active antiretroviral therapy (HAART), the lifesaving treatment for patients with HIV/AIDS, is an important component of the overall treatment plan.[@b3-hiv-9-153] Since its introduction, the impact of HIV infection has significantly decreased.[@b4-hiv-9-153] The goal of the treatment is to suppress virus replication for as long as possible, restore and/or preserve immune function, improve quality of life, and reduce HIV-related morbidity and mortality.[@b5-hiv-9-153]--[@b7-hiv-9-153] But this has not always been apparent as many of the patients experience deterioration and develop treatment failure, which can be explained by virological, clinical, or immunological causes or all of these because they do not behave according to expectations.[@b7-hiv-9-153]

Virological failure, which is a more informative treatment failure, is a common problem that an HIV patient faces after starting treatment.[@b8-hiv-9-153],[@b9-hiv-9-153] Current guidelines recommend that once patients start treatment, virological failure should not exceed 10%.[@b8-hiv-9-153],[@b10-hiv-9-153] However, studies show that virological failure is much higher than expected,[@b11-hiv-9-153]--[@b16-hiv-9-153] and viral replication continues to be a major challenge among patients living with HIV.[@b11-hiv-9-153],[@b17-hiv-9-153] Patients who experienced virological failure were found to have an increased risk of clinical progression to AIDS and mortality when compared with patients with complete virological response.[@b17-hiv-9-153] Previous studies revealed that various factors were associated with virological failure. Accordingly, baseline CD4 count,[@b15-hiv-9-153],[@b17-hiv-9-153]--[@b19-hiv-9-153] younger age,[@b12-hiv-9-153],[@b14-hiv-9-153],[@b20-hiv-9-153],[@b21-hiv-9-153] longer time on HAART,[@b15-hiv-9-153],[@b16-hiv-9-153],[@b20-hiv-9-153] poor adherence to treatment,[@b20-hiv-9-153]--[@b23-hiv-9-153] and last lower CD4 count[@b16-hiv-9-153],[@b24-hiv-9-153] were associated with virological failure. On the other hand, extra baseline weight was negatively associated with virological failure.

Identifying and managing determinants of virological failure are of paramount importance to achieve a high treatment success rate and improve the quality of life. However, there is limited evidence on the determinants of virological failure among HIV-infected patients on HAART in Ethiopia and in the study area. Thus, this study aimed to identify the determinants of virological failure among HIV-infected patients on HAART at the University of Gondar Referral Hospital, Northwest Ethiopia.

Methods
=======

Study design and setting
------------------------

A hospital-based case--control study was conducted from May to June 2015 at the University of Gondar Referral Hospital. This hospital is a pioneer health facility located in Gondar district 748 km from Addis Ababa, the capital of Ethiopia, and provides health care services to \>5 million residents of Northwest Ethiopia. The chronic HIV care center was launched in 2003 and free ART started in 2006. The service is provided in the Adult, Pediatric ART, and Prevention of Mother to Child Transmission (PMTCT) clinics. Ever since the launching of the care, about 12,470 HIV-infected clients were enrolled in the ART clinic. Out of these, 8,220 started ART and 5,138 are on HAART currently.

Study participants and sample size determination
------------------------------------------------

All HIV-infected adults aged ≥15 years and had been enrolled for ART with documented viral load results from 2010 to 2015 were included in the study. However, clients who had a follow-up of \<6 months at the University of Gondar Referral Hospital were excluded.

All HIV-infected adults whose plasma viral load of ≥1,000 copies/mL in 2 consecutive viral load measurements in a 3-month interval after 6 months of starting a new ART regimen were defined as cases (virological failure) with adherent support, while study participants with a viral load level of \<1,000 copies/mL were considered as controls.[@b10-hiv-9-153]

Sample size was determined using Epi Info™ 7 Stat-Calc by taking the key predictor of virological failure (poor adherence) from a previous study.[@b20-hiv-9-153] Therefore, the calculated sample size was 208 (104 cases and 104 controls). However, to improve the power of the study, all of the cases (153) and comparable controls (153) were included in the study. Controls were selected by using simple random sampling techniques.

Data collection tools and procedure
-----------------------------------

Data were extracted from patient charts using a pretested structured checklist. Accordingly, all charts containing detailed information about patients who were on HAART from 2010 to 2015 were reviewed. Six health professionals trained for 2 days collected the data. The principal investigator and the supervisor closely monitored the whole data collection process on a daily basis. Adherence to treatment was determined using the World Health Organization (WHO) definition in the follow-up chart. Thus, poor adherence to treatments is defined as patients taking ≤95% of the recommended regimens.[@b7-hiv-9-153]

Statistical analysis
--------------------

Data were entered into Epi Info version 7 and analyzed using SPSS version 20. Descriptive statistics, including mean values and frequencies, were used to describe demographic, clinical, hematologic, and medication-related characteristics of patients. Bivariate analysis was carried out for all independent variables with an outcome variable. Using variables with a *p*-value of up to 0.2, according to the bivariate analysis, a multivariate logistic regression analysis was carried out to identify the independent determinants of virological failure. The Hosmer--Lemeshow goodness-of-fit test for the model was also checked. Finally, variables that had significant associations with virological failure were identified based on the odds ratio (OR) with a 95% CI and *p*-values \<0.05.

Ethical considerations
----------------------

Informed consent was waived by the Institutional Ethical Review Board of the University of Gondar and the Chief Clinical Officer of the University of Gondar Referral Hospital for this retrospective chart review, as all the data were de-identified. The confidentiality of information obtained from each study participant was guaranteed by omitting names or any personal identifiers. Moreover, the collected data were kept safe throughout the whole process of the research work to limit data accessibility to a third party.

Results
=======

Sociodemographic characteristics
--------------------------------

At baseline, the mean age of the cases and the controls was 32 years (SD: ±7 years) and 36 years (SD: ±10 years), respectively. Moreover, 80 (53.6%) of cases and 79 (51.6%) of the controls were females; 138 (90.2%) of the cases and 132 (86.3%) of the controls were Orthodox Christians. More than three-quarters (75.8% and 79.7%) of the cases and controls, respectively, were urban dwellers ([Table 1](#t1-hiv-9-153){ref-type="table"}).

Clinical-related characteristics
--------------------------------

Among the participants, 121 (79.1%) cases and 111 (72.5%) controls were classified as stages III and IV at baseline. Moreover, 33 (21.6%) of the cases and 20 (13.1%) of the controls developed tuberculosis (TB) before initiation of HAART, while one-quarter (26.1% and 28.8%) of the cases and controls, respectively, acquired TB after enrollment in HAART ([Table 2](#t2-hiv-9-153){ref-type="table"}).

Antiretroviral medication-related characteristics
-------------------------------------------------

Almost half (49.7%) of the cases and only 12 (7.8%) of the controls had history of poor adherence to treatment. Nearly three-fourths (71.2%) of the cases and half (49.1%) of the controls were on HAART for ≥48 months ([Table 3](#t3-hiv-9-153){ref-type="table"}).

Hematologic profile of the study participants
---------------------------------------------

In this study, 135 (88.2%) of the cases and 121 (78.9%) of the controls had \<200 cells/mm^3^ CD4 count at baseline, while 125 (81.7%) of the cases and 74 (48.4%) of the controls had CD4 count \<200 cells/mm^3^ at the previous visit.

Factors associated with HIV virological failure
-----------------------------------------------

The bivariate logistic regression analysis showed that age, educational status, occupation, ART medication adherence, TB coinfection, baseline WHO clinical stage, current body mass index (BMI), first-line ART, duration on ART, baseline and recent CD4 count, current WBC count, and hemoglobin level were associated with antiretroviral virological failure.

After adjustment for possible effects of confounding variables, patients aged \<35 years, with recent CD4 count \<200 cells/mm^3^, poor adherence to ART, and longer duration of ART enrollment were significantly associated with virological failure.

The likelihood of developing virological failure for patients aged \<35 years was 2.5 times (adjusted OR \[AOR\] =2.52, 95% CI: 1.33, 4.77) as likely as compared with their older counterparts. Patients who had had a recent CD4 count of \<200 cells/mm^3^ were 9 times (AOR=9.03, 95% CI: 4.40, 18.50) as likely to have virological failure as those with higher CD4 counts. Patients who were poorly adherent to their ART were 16 times (AOR=15.80, 95% CI: 6.90, 36.50) as likely to have virological failure as compared to those who were adherent to their treatment. Patients who took ART for 24--47 months and for \>48 months were 3 times (AOR=3.00, 95% CI: 1.10, 8.40) and 7 times (AOR=6.7, 95% CI: 2.7, 16.60), respectively, as likely to have virological failure as those who took the treatment for 6--24 months ([Table 4](#t4-hiv-9-153){ref-type="table"}).

Discussion
==========

This study investigated the determinants of ART virological failure and revealed that patients aged \<35 years, with recent low CD4 count (\<200 cells/mm^3^), poor adherence to treatment, and longer duration on HAART enrollment were found to have increased odds of virological failure.

In this study, patients aged \<35 years were associated with virological failure. Similar findings were reported from Nyanza region, Kenya,[@b12-hiv-9-153] Cameroon,[@b14-hiv-9-153] Mozambique,[@b20-hiv-9-153] and France,[@b21-hiv-9-153] where the likelihood of developing ART virological failure was higher among younger patients. This might be due to differences in lifestyles, as most of the younger adults commonly suffered from less healthy personality traits and were more vulnerable to substance abuse. Moreover, they had less emotional stability to cope with the social stigma, discrimination, and the adverse consequences of the disease itself. This suggests that depression, anxiety, and unhealthy behaviors could negatively affect dietary intake and treatment outcomes of clients.[@b25-hiv-9-153]

Patients with a recent low CD4 count were 9 times as likely to develop virological failure as those with higher CD4 count (\>200 cells/mm^3^). The finding was consistent with those of studies conducted in Swaziland[@b16-hiv-9-153] and northwestern Uganda.[@b24-hiv-9-153] It is well known that CD4 count has an inverse relationship with viral replication and load. As patients' immune status becomes compromised, the rate of viral replication increases compared to their immune-competent counterparts. Furthermore, clients with compromised immunity are more vulnerable to different opportunistic infections that sustain the vicious cycle of immunity and viral replication.[@b6-hiv-9-153]

Adherence to ART was also an important determinant of virological failure. Patients with poor medication adherence were 16 times as likely to develop virological failure as patients with good adherence. The finding was consistent with those of studies conducted in Mozambique,[@b20-hiv-9-153] France,[@b21-hiv-9-153] China,[@b22-hiv-9-153] and Guangxi, China,[@b23-hiv-9-153] where poor medication adherence was the main risk factor for virological failure. It is evident that individuals missing 3 doses of ART per month are associated with an increased risk of drug resistance and reduced immunity.[@b6-hiv-9-153] This results in the loss of the opportunity to suppress viral replication and leads to virological failure.[@b7-hiv-9-153]

Duration of ART was a significant factor associated with virological failure. This study showed that the likelihood of virological failure was 3 and 7 times more among patients who took ART for \~24--47 months and ≥48 months, respectively, compared to patients who took the treatment for 6--24 months. This finding is supported by studies conducted in Gabon,[@b15-hiv-9-153] Swaziland,[@b16-hiv-9-153] and Mozambique.[@b20-hiv-9-153] The possible reason might be that as the duration of ART increased, the likelihood of developing poor adherence and drug interruption, as well as drug side effects, also increased.[@b6-hiv-9-153] All these factors might have led to virological failure.

Conclusion
==========

This study showed that age \<35 years, low CD4 count, poor adherence to treatment, and higher duration of taking ART were positively and significantly associated with virological failure. Therefore, efforts should be strengthened to improve adherence to ART, which helps to boost immunity and suppress viral replication and load. Moreover, more attention should be given to younger patients who have taken ART for a prolonged duration.
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###### 

Sociodemographic characteristics of HIV-infected patients treated at the University of Gondar Referral Hospital: 2010--2015

  Variables                                          Cases        Controls
  -------------------------------------------------- ------------ ------------
  Age, years                                                      
   \<35                                              99 (64.7)    73 (47.7)
   ≥35                                               54 (35.3)    80 (52.3)
  Sex                                                             
   Male                                              71 (46.4)    74 (48.4)
   Female                                            82 (53.6)    79 (51.6)
  Residence                                                       
   Urban                                             116 (75.8)   122 (79.7)
   Rural                                             37 (24.2)    31 (20.3)
  Marital status                                                  
   Never married                                     35 (22.9)    31 (20.3)
   Married                                           65 (42.5)    47 (30.7)
   Others[a](#tfn1-hiv-9-153){ref-type="table-fn"}   53 (34.6)    75 (49.0)
  Educational level                                               
   No schooling                                      42 (27.5)    34 (22.2)
   Primary school                                    55 (35.9)    34 (22.2)
   Secondary school                                  56 (36.6)    85 (55.6)
  Religion                                                        
   Orthodox                                          138 (90.2)   132 (86.3)
   Others[b](#tfn2-hiv-9-153){ref-type="table-fn"}   15 (9.8)     21 (13.7)
  Occupation                                                      
   Not employed                                      48 (31.4)    50 (32.7)
   Government employed                               24 (15.7)    42 (27.5)
   Self--employed                                    41 (26.8)    31 (20.2)
   Daily laborer                                     40 (26.1)    30 (19.6)

**Notes:**

Divorced, separated, or widowed;

Muslim or Protestant.

###### 

Behavioral and clinical-related information among HIV-positive adults who have had follow-up at the University of Gondar Referral Hospital: 2010--2015

  Variables                   Cases        Controls
  --------------------------- ------------ ------------
  Baseline BMI, kg/m^2^                    
   \<16.5                     22 (14.4)    19 (11.8)
   16.5--18.49                48 (31.4)    49 (32.2)
   ≥18.5                      83 (54.2)    85 (55.9)
  Current BMI, kg/m^2^                     
   \<16.50                    28 (18.3)    17 (10.5)
   16.50--18.49               27 (17.6)    28 (18.4)
   ≥18.50                     98 (64.1)    108 (71.1)
  WHO clinical stage                       
   Stages I and II            32 (20.9)    42 (27.5)
   Stages III and IV          121 (79.1)   111 (72.5)
  History of TB                            
   Before ART                 33 (21.6)    20 (13.1)
   After ART                  40 (26.1)    44 (28.8)
  Duration with HIV, months                
   6--24                      9 (5.9)      28 (18.3)
   24--47                     30 (19.6)    46 (30.1)
   ≥48                        114 (74.5)   79 (51.6)
  History of substance use                 
   Yes                        27 (17.6)    35 (22.9)
   No                         126 (82.4)   118 (77.1)

**Abbreviations:** ART, antiretroviral therapy; BMI, body mass index; TB, tuberculosis.

###### 

Antiretroviral medication-related information among HIV-positive adults who have had follow-up at the University of Gondar Referral Hospital: 2010--2015

  Variables                                   Cases        Controls
  ------------------------------------------- ------------ ------------
  Adherence to treatment                                   
   Good                                       77 (50.3)    141 (92.2)
   Poor                                       76 (49.7)    12 (7.8)
  CPT use                                                  
   Yes                                        142 (92.8)   139 (90.8)
   No                                         11 (7.2)     14 (9.2)
  First-line ART regimen                                   
   AZT based                                  48 (31.4)    78 (51.0)
   TDF based                                  40 (26.1)    37 (24.2)
   D4T based                                  65 (42.5)    38 (24.8)
  Change of ARV regimen or individual drugs                
   Yes                                        73 (47.7)    72 (47.1)
   No                                         80 (52.3)    81 (52.9)
  ART regimen at the time of VL test                       
   TDF based                                  67 (43.8)    63 (41.2)
   AZT based                                  86 (56.2)    90 (58.8)
  ART duration, months                                     
   6--24                                      13 (8.5)     38 (24.8)
   24--47                                     31 (20.3)    40 (26.1)
   ≥48                                        109 (71.2)   75 (49.1)

**Abbreviations:** ART, antiretroviral therapy; ARV, antiretroviral; AZT, azidothymidine; BMI, body mass index; CPT, cotrimoxazole preventive therapy; D4T, stavudine; TB, tuberculosis; TDF, tenofovir disoproxil fumarate; VL, viral load.

###### 

Determinants of ART virological failure among HIV-positive adults who had follow-up at the University of Gondar Referral Hospital: 2010--2015

  Variables                         Virological failure   COR (95% CI)   AOR (95% CI)                                                  
  --------------------------------- --------------------- -------------- ------------------------------------------------------------- -------------------------------------------------------------
  Age, years                                                                                                                           
   \<35                             99 (64.7)             73 (47.7       2.00 (1.27, 3.18)[\*](#tfn5-hiv-9-153){ref-type="table-fn"}   2.52 (1.33,4.77)[\*](#tfn5-hiv-9-153){ref-type="table-fn"}
   ≥35                              54 (35.3)             80 (52.3)      1                                                             --
  Educational status                                                                                                                   
   No schooling                     42 (27.5)             34 (22.2)      1                                                             --
   Primary                          55 (35.9)             34 (22.2)      1.88 (1.07, 3.23)[\*](#tfn5-hiv-9-153){ref-type="table-fn"}   --
   Secondary                        56 (36.6)             85 (55.6)      2.56 (1.42,4.23)[\*](#tfn5-hiv-9-153){ref-type="table-fn"}    --
  Occupation                                                                                                                           
   Unemployed                       48 (31.4)             50 (32.7)      1                                                             --
   Employed                         24 (15.7)             42 (27.5)      0.59 (0.31, 1.13)                                             --
   Self-employed                    41 (26.8)             31 (20.3)      1.38 (0.75, 2.54)                                             --
   Daily laborer                    40 (26.1)             30 (19.6)      1.39 (0.75, 2.57)                                             --
  WHO clinical stage                                                                                                                   
   Stages I and II                  32 (20.9)             42 (27.5)      1                                                             --
   Stages III and IV                121 (79.1)            111 (72.5)     1.43 (0.84,2.42)                                              --
  Adherence                                                                                                                            
   Good                             77 (50.3)             141 (92.2)     1                                                             --
   Poor                             76 (49.7)             12 (7.8)       12.4 (6.26, 24.9)[\*](#tfn5-hiv-9-153){ref-type="table-fn"}   15.8 (6.90,36.50)[\*](#tfn5-hiv-9-153){ref-type="table-fn"}
  History of TB                                                                                                                        
   No TB                            80 (52.3)             89 (58.2)      1                                                             --
   Before ART                       33 (21.6)             20 (13.1)      1.84 (0.976, 3.45)                                            --
   After ART                        40 (26.1)             44 (28.7)      1.01 (0.60, 1.71)                                             --
  First-line ART regimen                                                                                                               
   D4T based                        65 (42.5)             38 (24.8)      0.36 (0.21, 0.62)[\*](#tfn5-hiv-9-153){ref-type="table-fn"}   --
   AZT based                        48 (31.4)             78 (51.0)      0.63 (0.34, 1.14)                                             --
   TDF based                        40 (26.1)             37 (24.2)      1                                                             --
  Duration on ART, months                                                                                                              
   6--24                            13 (8.5)              38 (24.8)      1                                                             1
   24--47                           31 (20.3)             40 (26.1)      2.26 (1.03, 4.97)[\*](#tfn5-hiv-9-153){ref-type="table-fn"}   3.00 (1.10, 8.40)[\*](#tfn5-hiv-9-153){ref-type="table-fn"}
   ≥48                              109 (71.2)            75 (49.1)      4.25 (2.12, 8.52)[\*](#tfn5-hiv-9-153){ref-type="table-fn"}   6.7 (2.7, 16.60)[\*](#tfn5-hiv-9-153){ref-type="table-fn"}
  Current BMI, kg/m^2^                                                                                                                 
   \<16.5                           28 (18.3)             17 (10.5)      1.92 (0.98, 3.78)                                             --
   16.5--18.49                      27 (17.6)             28 (18.4)      1.06 (0.58,1.97)                                              --
   ≥18.5                            98 (64.1)             108 (71.1)     1                                                             --
  Current WBC count, cells/mm^3^                                                                                                       
   \<4,000                          59 (37.8)             36 (23.8)      1.94 (1.18, 3.20)[\*](#tfn5-hiv-9-153){ref-type="table-fn"}   --
   ≥4,000                           94 (62.2)             117 (76.2)     1                                                             --
  Current hemoglobin level, g/dL                                                                                                       
   \<12                             37 (24.2)             24 (15.9)      1.68 (0.95, 2.99)                                             --
   ≥12                              116 (75.8)            129 (84.1)     1                                                             --
  Baseline CD4 count, cells/mm^3^                                                                                                      
   \<200                            135 (88.2)            121 (79.1)     2.00 (1.07, 3.75)[\*](#tfn5-hiv-9-153){ref-type="table-fn"}   --
   ≥200                             18 (11.8)             32 (20.9)      1                                                             --
  Current CD4 count, cells/mm^3^                                                                                                       
   \<200                            125 (81.7)            74 (48.4)      4.77 (2.84, 8.00)[\*](#tfn5-hiv-9-153){ref-type="table-fn"}   9.03 (4.40,18.50)[\*](#tfn5-hiv-9-153){ref-type="table-fn"}
   ≥200                             28 (18.3)             79 (51.6)      1                                                             1

**Notes:**

Significant at a *p*-value of \<0.05; Hosmer--Lemeshow test =0.702.

**Abbreviations:** AOR, adjusted odds ratio; ART, antiretroviral therapy; AZT, azidothymidine; BMI, body mass index; COR, crude odds ratio; D4T, stavudine; TB, tuberculosis; TDF, tenofovir disoproxil fumarate.
